Alexander W. Casdin net worth and biography

Alexander Casdin Biography and Net Worth

Director of Erasca

Alex is the CEO and a member of the board of directors of Epirium Bio, a biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases. Previously, Alex was the COO and CFO of Epirium. Prior to joining Epirium, Alex was founder, CEO and Portfolio Manager of Reneo Capital Management LP. A successful healthcare investor and executive, Alex brings more than 20 years of experience shaping and advising biopharmaceutical companies. Prior to forming Reneo, he served in roles including CFO of Sophiris Bio and Vice President of Finance of Amylin Pharmaceuticals. Previously, he served as a board member for Ignyta; and he ran Casdin Advisors LLC, providing strategic advice to life science companies, including Amylin. Before founding Casdin Advisors, Alex was CEO and Portfolio Manager of Cooper Hill Partners LLC, a healthcare investment fund, and before that, as Portfolio Manager of Pequot Capital Management’s healthcare fund. Earlier, Alex worked at the Dreyfus Corporation as a Senior Managing Analyst covering pharmaceuticals, biotechnology and medical devices. He also served as a Legislative Assistant to Congressman Robert J. Mrazek (D-NY) and then as Legislative Affairs Specialist for Patton Boggs LLP in Washington, D.C. He also is a board member, treasurer and executive committee member of the Conquer Cancer foundation of the American Society of Clinical Oncology, and a member of Brown University’s Advisory Council on Biology and Medicine.

What is Alexander W. Casdin's net worth?: The estimated net worth of Alexander W. Casdin is at least $1.83 million as of May 21st, 2024. Mr. Casdin owns 573,974 shares of Erasca stock worth more than $1,830,977 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Casdin may own. Learn More about Alexander W. Casdin's net worth.
How do I contact Alexander W. Casdin?: The corporate mailing address for Mr. Casdin and other Erasca executives is , , . Erasca can also be reached via phone at 858-465-6511 and via email at [email protected]. Learn More on Alexander W. Casdin's contact information.
Has Alexander W. Casdin been buying or selling shares of Erasca?: Alexander W. Casdin has not been actively trading shares of Erasca during the last ninety days. Most recently, on Tuesday, May 21st, Alexander W. Casdin bought 80,000 shares of Erasca stock. The stock was acquired at an average cost of $2.27 per share, with a total value of $181,600.00. Following the completion of the transaction, the director now directly owns 573,974 shares of the company's stock, valued at $1,302,920.98. Learn More on Alexander W. Casdin's trading history.
Who are Erasca's active insiders?: Erasca's insider roster includes Alexander Casdin (Director), Valerie Harding (Director), and Jonathan Lim (Chairman, CEO and Co-founder). Learn More on Erasca's active insiders.

Alexander W. Casdin Insider Trading History at Erasca

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/21/2024	Buy	80,000	$2.27	$181,600.00	573,974
12/4/2023	Buy	30,000	$1.66	$49,800.00	493,974
4/10/2023	Buy	20,000	$2.76	$55,200.00	463,974
12/15/2022	Buy	20,000	$4.87	$97,400.00	443,974

Alexander W. Casdin Buying and Selling Activity at Erasca

Erasca Company Overview

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Today's Range

Now: $3.19

$3.17

$3.36

50 Day Range

MA: $2.54

$2.08

$3.29

2 Week Range

Now: $3.19

$1.01

$3.38

Volume

3,227,137 shs

Average Volume

1,804,237 shs

Market Capitalization

$905.03 million

P/E Ratio

N/A

Dividend Yield